sulforaphane has been researched along with Diabetes Mellitus, Adult-Onset in 23 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulforaphane (SFN) is a natural antioxidant extracted from the cruciferous vegetables." | 5.72 | Sulforaphane alleviates high fat diet-induced insulin resistance via AMPK/Nrf2/GPx4 axis. ( Gao, Y; Liu, J; Ma, X; Thring, RW; Tong, H; Wu, M; Wu, Q; Zhang, Y; Zhang, Z; Zhu, J, 2022) |
| "SFN may prevent different types of cancer and has the ability to improve hypertensive states, to prevent type 2 diabetes-induced cardiomyopathy, and to protect against gastric ulcer." | 2.72 | Potential of Sulforaphane as a Natural Immune System Enhancer: A Review. ( Castillo, A; Mahn, A, 2021) |
| " To allow comparison between rodent and human studies, we discuss the published bioavailability of SFN metabolites achieved in rodents and man in the context of Nrf2, NFκB and PPARγ signaling." | 2.58 | Concerted redox modulation by sulforaphane alleviates diabetes and cardiometabolic syndrome. ( Chapple, SJ; Mann, GE; Patel, B, 2018) |
| "Sulforaphane (SFN) is a natural antioxidant extracted from the cruciferous vegetables." | 1.72 | Sulforaphane alleviates high fat diet-induced insulin resistance via AMPK/Nrf2/GPx4 axis. ( Gao, Y; Liu, J; Ma, X; Thring, RW; Tong, H; Wu, M; Wu, Q; Zhang, Y; Zhang, Z; Zhu, J, 2022) |
| "Sulforaphane (SFN) has been proven to be effective in alleviating many metabolic diseases, such as obesity and type 2 diabetes." | 1.72 | The protective effects of sulforaphane on high-fat diet-induced metabolic associated fatty liver disease in mice ( Hu, Q; Li, X; Lu, Y; Ma, S; Pang, X; Sun, J; Tian, S, 2022) |
| "Sulforaphane (SFN) is an organic isothiocyanate found in cruciferous plants." | 1.56 | Sulforaphane protects against skeletal muscle dysfunction in spontaneous type 2 diabetic db/db mice. ( Chen, J; Liao, Z; Lu, A; Pu, D; Sun, Y; Wang, M; Xiao, Q; Zhao, Y; Zhu, S, 2020) |
| "Sulforaphane (SFN) prevents diabetic nephropathy (DN) in type 2 diabetes (T2D) by up-regulating nuclear factor (erythroid-derived 2)-like 2 (Nrf2)." | 1.56 | Sulforaphane prevents type 2 diabetes-induced nephropathy via AMPK-mediated activation of lipid metabolic pathways and Nrf2 antioxidative function. ( Cai, L; Guo, H; Li, J; Li, Z; Ma, T; Miao, L; Zhang, Z; Zhou, S, 2020) |
| "Sulforaphane (SFN) is a pharmacological activator of Nrf2 that provokes Nrf2-mediated intracellular defenses, including antioxidant and anti-inflammatory responses, under oxidative stress (OS) conditions." | 1.48 | Protective Effects of Sulforaphane on Cognitive Impairments and AD-like Lesions in Diabetic Mice are Associated with the Upregulation of Nrf2 Transcription Activity. ( Chen, J; Luo, C; Lv, A; Pu, D; Sun, Y; Xiao, Q; Zhao, K; Zhao, Y; Zhu, S, 2018) |
| " Metabolic profile, NO bioavailability and vascular oxidative stress, AGE and Nrf2 levels were also assessed." | 1.46 | The Sulforaphane and pyridoxamine supplementation normalize endothelial dysfunction associated with type 2 diabetes. ( Crisóstomo, J; Fernandes, R; Pereira, A; Seiça, RM; Sena, CM, 2017) |
| "Sulforaphane (SFN) prevents diabetic nephropathy (DN) in type 1 diabetes via up-regulation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2)." | 1.42 | Metallothionein plays a prominent role in the prevention of diabetic nephropathy by sulforaphane via up-regulation of Nrf2. ( Cai, L; Chen, X; Cheng, Y; Kong, L; Luo, M; Miao, L; Tan, Y; Wang, Y; Wu, H; Zhang, Z, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (60.87) | 24.3611 |
| 2020's | 9 (39.13) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 2 |
| Wu, Q | 1 |
| Liu, J | 1 |
| Zhang, Z | 8 |
| Ma, X | 1 |
| Zhu, J | 1 |
| Thring, RW | 1 |
| Wu, M | 1 |
| Gao, Y | 1 |
| Tong, H | 1 |
| Ma, S | 3 |
| Pang, X | 3 |
| Tian, S | 3 |
| Sun, J | 5 |
| Hu, Q | 3 |
| Li, X | 3 |
| Lu, Y | 3 |
| Ye, X | 1 |
| Toyama, T | 1 |
| Taguchi, K | 1 |
| Arisawa, K | 1 |
| Kaneko, T | 1 |
| Tsutsumi, R | 1 |
| Yamamoto, M | 1 |
| Saito, Y | 1 |
| Mohamadi, N | 1 |
| Baradaran Rahimi, V | 1 |
| Fadaei, MR | 1 |
| Sharifi, F | 1 |
| Askari, VR | 1 |
| Sun, Y | 3 |
| Zhou, S | 3 |
| Guo, H | 2 |
| Zhang, J | 1 |
| Ma, T | 2 |
| Zheng, Y | 4 |
| Cai, L | 7 |
| Wang, M | 1 |
| Pu, D | 2 |
| Zhao, Y | 2 |
| Chen, J | 4 |
| Zhu, S | 2 |
| Lu, A | 1 |
| Liao, Z | 1 |
| Xiao, Q | 2 |
| Li, Z | 1 |
| Li, J | 1 |
| Miao, L | 2 |
| Clifford, T | 1 |
| Acton, JP | 1 |
| Cocksedge, SP | 1 |
| Davies, KAB | 1 |
| Bailey, SJ | 1 |
| Mahn, A | 1 |
| Castillo, A | 1 |
| Axelsson, AS | 1 |
| Tubbs, E | 1 |
| Mecham, B | 1 |
| Chacko, S | 1 |
| Nenonen, HA | 1 |
| Tang, Y | 1 |
| Fahey, JW | 2 |
| Derry, JMJ | 1 |
| Wollheim, CB | 1 |
| Wierup, N | 1 |
| Haymond, MW | 1 |
| Friend, SH | 1 |
| Mulder, H | 1 |
| Rosengren, AH | 1 |
| McDonnell, C | 1 |
| Leánez, S | 1 |
| Pol, O | 1 |
| Pereira, A | 1 |
| Fernandes, R | 1 |
| Crisóstomo, J | 1 |
| Seiça, RM | 1 |
| Sena, CM | 1 |
| Patel, B | 1 |
| Mann, GE | 1 |
| Chapple, SJ | 1 |
| Palliyaguru, DL | 1 |
| Yuan, JM | 1 |
| Kensler, TW | 1 |
| Lv, A | 1 |
| Luo, C | 1 |
| Zhao, K | 1 |
| Pulakazhi Venu, VK | 1 |
| El-Daly, M | 1 |
| Saifeddine, M | 1 |
| Hirota, SA | 1 |
| Ding, H | 1 |
| Triggle, CR | 1 |
| Hollenberg, MD | 1 |
| Velmurugan, GV | 1 |
| Sundaresan, NR | 1 |
| Gupta, MP | 1 |
| White, C | 1 |
| Wang, Y | 4 |
| Sun, W | 1 |
| Tan, Y | 5 |
| Liu, Y | 1 |
| Liu, Q | 1 |
| Wang, S | 3 |
| Yan, X | 1 |
| Mellen, N | 1 |
| Kong, M | 1 |
| Gu, J | 2 |
| Wu, H | 2 |
| Kong, L | 2 |
| Cheng, Y | 2 |
| Luo, M | 1 |
| Chen, X | 1 |
| Xu, Z | 3 |
| Ji, H | 1 |
| Wintergerst, K | 1 |
| Keller, BB | 1 |
| Zhou, H | 1 |
| Bahadoran, Z | 1 |
| Tohidi, M | 1 |
| Nazeri, P | 1 |
| Mehran, M | 1 |
| Azizi, F | 1 |
| Mirmiran, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes[NCT02801448] | Phase 2 | 103 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Effect of Consumption of a Lyophilized Nasturtium (Tropaeolum Majus L), on the Insulin Response, Lipid Profile, Antioxidant Capacity and Gene Expression in Pre-diabetic Subjects: Bogotá-Colombia[NCT05346978] | 10 participants (Actual) | Interventional | 2018-06-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for sulforaphane and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
A mechanistic overview of sulforaphane and its derivatives application in diabetes and its complications.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Humans; Isothiocy | 2023 |
The effect of dietary phytochemicals on nuclear factor erythroid 2-related factor 2 (Nrf2) activation: a systematic review of human intervention trials.
Topics: Adult; Aged; Antioxidants; Bias; Curcumin; Diabetes Mellitus, Type 2; Humans; Isothiocyanates; Middl | 2021 |
Potential of Sulforaphane as a Natural Immune System Enhancer: A Review.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Immune System; Isothiocyanates; | 2021 |
Concerted redox modulation by sulforaphane alleviates diabetes and cardiometabolic syndrome.
Topics: Antioxidants; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Isothiocyanates; Metabolic | 2018 |
Isothiocyanates: Translating the Power of Plants to People.
Topics: Brassica; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Isot | 2018 |
1 trial available for sulforaphane and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effect of broccoli sprouts on insulin resistance in type 2 diabetic patients: a randomized double-blind clinical trial.
Topics: Adult; Antioxidants; Blood Glucose; Brassica; Diabetes Mellitus, Type 2; Dietary Supplements; Double | 2012 |
17 other studies available for sulforaphane and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Sulforaphane alleviates high fat diet-induced insulin resistance via AMPK/Nrf2/GPx4 axis.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Diabetes Mellitus, Type 2; Diet, High-Fat; Ins | 2022 |
The protective effects of sulforaphane on high-fat diet-induced metabolic associated fatty liver disease in mice
Topics: Animals; Bile Acids and Salts; Diabetes Mellitus, Type 2; Diet, High-Fat; Liver; Mice; Mice, Inbred | 2022 |
The protective effects of sulforaphane on high-fat diet-induced metabolic associated fatty liver disease in mice
Topics: Animals; Bile Acids and Salts; Diabetes Mellitus, Type 2; Diet, High-Fat; Liver; Mice; Mice, Inbred | 2022 |
The protective effects of sulforaphane on high-fat diet-induced metabolic associated fatty liver disease in mice
Topics: Animals; Bile Acids and Salts; Diabetes Mellitus, Type 2; Diet, High-Fat; Liver; Mice; Mice, Inbred | 2022 |
The protective effects of sulforaphane on high-fat diet-induced metabolic associated fatty liver disease in mice
Topics: Animals; Bile Acids and Salts; Diabetes Mellitus, Type 2; Diet, High-Fat; Liver; Mice; Mice, Inbred | 2022 |
Sulforaphane decreases serum selenoprotein P levels through enhancement of lysosomal degradation independent of Nrf2.
Topics: Animals; Diabetes Mellitus, Type 2; Lysosomes; Mice; NF-E2-Related Factor 2; Selenoprotein P | 2023 |
Protective effects of sulforaphane on type 2 diabetes-induced cardiomyopathy via AMPK-mediated activation of lipid metabolic pathways and NRF2 function.
Topics: AMP-Activated Protein Kinases; Animals; Cardiotonic Agents; Diabetes Mellitus, Experimental; Diabete | 2020 |
Sulforaphane protects against skeletal muscle dysfunction in spontaneous type 2 diabetic db/db mice.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Heme Oxygenase-1; | 2020 |
Sulforaphane prevents type 2 diabetes-induced nephropathy via AMPK-mediated activation of lipid metabolic pathways and Nrf2 antioxidative function.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Nephropath | 2020 |
Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes.
Topics: Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Female; Glucose; Glycated Hemoglobin; | 2017 |
The induction of the transcription factor Nrf2 enhances the antinociceptive effects of delta-opioid receptors in diabetic mice.
Topics: Animals; Benzamides; Blood Glucose; Blotting, Western; Body Weight; Diabetes Mellitus, Experimental; | 2017 |
The Sulforaphane and pyridoxamine supplementation normalize endothelial dysfunction associated with type 2 diabetes.
Topics: Animals; Aorta; Diabetes Mellitus, Type 2; Dietary Supplements; Disease Models, Animal; Endothelium; | 2017 |
Protective Effects of Sulforaphane on Cognitive Impairments and AD-like Lesions in Diabetic Mice are Associated with the Upregulation of Nrf2 Transcription Activity.
Topics: Alzheimer Disease; Animals; Antioxidants; Cognitive Dysfunction; Diabetes Mellitus, Experimental; Di | 2018 |
Minimizing Hyperglycemia-Induced Vascular Endothelial Dysfunction by Inhibiting Endothelial Sodium-Glucose Cotransporter 2 and Attenuating Oxidative Stress: Implications for Treating Individuals With Type 2 Diabetes.
Topics: Biomarkers; Biopterins; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic | 2019 |
Defective Nrf2-dependent redox signalling contributes to microvascular dysfunction in type 2 diabetes.
Topics: Animals; Arterioles; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glutamate-Cy | 2013 |
Sulforaphane attenuation of type 2 diabetes-induced aortic damage was associated with the upregulation of Nrf2 expression and function.
Topics: Animals; Aorta; Apoptosis; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 2014 |
Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1/AMPK pathway.
Topics: Adenylate Kinase; AMP-Activated Protein Kinases; Animals; Autophagy; Cardiotonic Agents; Diabetes Me | 2014 |
Metallothionein plays a prominent role in the prevention of diabetic nephropathy by sulforaphane via up-regulation of Nrf2.
Topics: Animals; Anticarcinogenic Agents; Blotting, Western; Diabetes Mellitus, Experimental; Diabetes Melli | 2015 |
Broccoli sprout extract prevents diabetic cardiomyopathy via Nrf2 activation in db/db T2DM mice.
Topics: Animals; Brassica; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Gen | 2016 |
Metallothionein Is Downstream of Nrf2 and Partially Mediates Sulforaphane Prevention of Diabetic Cardiomyopathy.
Topics: Animals; Anticarcinogenic Agents; Blotting, Western; Diabetes Mellitus, Experimental; Diabetes Melli | 2017 |